Nektar Therapeutics
NKTR
231 hedge funds and large institutions have $561M invested in Nektar Therapeutics in 2022 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 70 increasing their positions, 74 reducing their positions, and 25 closing their positions.
814% more call options, than puts
Call options by funds: $2M | Put options by funds: $219K
20% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 25
1% more funds holding
Funds holding: 228 → 231 (+3)
0.3% less ownership
Funds ownership: 6.53% → 6.24% (-0.3%)
5% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 74
19% less capital invested
Capital invested by funds: $694M → $561M (-$132M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.2M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$3.87M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.21M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$29.8M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
-$12.2M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.7M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$4.33M |
| 5 |
State Street
Boston,
Massachusetts
|
-$3.46M |
NKTR Hedge Fund Activity: Q3 2022 in Review
231 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2022, worth a combined $561M — down 19% from $694M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new NKTR positions and 25 closed out — a net gain of 5 holders — while 70 added to existing stakes and 74 trimmed.
The largest buyer was BlackRock, adding an estimated $13.8M. The largest seller was First Trust Advisors, exiting entirely with an estimated $29.8M sold.
- 231 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2022, up from 228 in Q2 2022.
- Funds reported $561M of Nektar Therapeutics stock for Q3 2022, down 19% quarter-over-quarter.
- 30 funds opened new Nektar Therapeutics positions in Q3 2022 and 25 closed out, a net change of +5 holders.
- The largest Nektar Therapeutics buyer in Q3 2022 was BlackRock, an estimated $13.8M added.
- The largest Nektar Therapeutics seller in Q3 2022 was First Trust Advisors, an estimated $29.8M sold.
Based on aggregated 13F filings for Q3 2022.